You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: June 14, 2024

Investigational Drug Information for troriluzole

✉ Email this page to a colleague

« Back to Dashboard

What is the development status for investigational drug troriluzole?

troriluzole is an investigational drug.

There have been 8 clinical trials for troriluzole. The most recent clinical trial was a Phase 3 trial, which was initiated on March 8th 2019.

The most common disease conditions in clinical trials are Disease, Obsessive-Compulsive Disorder, and Compulsive Personality Disorder. The leading clinical trial sponsors are Biohaven Pharmaceuticals, Inc., Alzheimer's Disease Cooperative Study (ADCS), and Dana-Farber Cancer Institute.

There are two US patents protecting this investigational drug and thirty-three international patents.

Recent Clinical Trials for troriluzole
Troriluzole or Placebo Plus Ipi Plus Nivo in Mel Brain MetsBiohaven Pharmaceuticals, Inc.Phase 2
Troriluzole or Placebo Plus Ipi Plus Nivo in Mel Brain MetsDana-Farber Cancer InstitutePhase 2
Long-term Safety Study of Adjunctive Troriluzole in Subjects With Obsessive Compulsive DisorderBiohaven Pharmaceuticals, Inc.Phase 3

See all troriluzole clinical trials

Clinical Trial Summary for troriluzole

Top disease conditions for troriluzole
Top clinical trial sponsors for troriluzole

See all troriluzole clinical trials

US Patents for troriluzole

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
troriluzole ⤷  Sign Up Riluzole prodrugs and their use Biohaven Therapeutics Ltd. (New Haven, CT) ⤷  Sign Up
troriluzole ⤷  Sign Up Prodrugs of riluzole and their method of use Biohaven Therapeutics Ltd. (New Haven, CT) ⤷  Sign Up
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for troriluzole

Drugname Country Document Number Estimated Expiration Related US Patent
troriluzole Australia AU2016226463 2035-03-03 ⤷  Sign Up
troriluzole Australia AU2020233650 2035-03-03 ⤷  Sign Up
troriluzole Australia AU2022202163 2035-03-03 ⤷  Sign Up
troriluzole Brazil BR112017018832 2035-03-03 ⤷  Sign Up
troriluzole Canada CA2978158 2035-03-03 ⤷  Sign Up
troriluzole China CN107567438 2035-03-03 ⤷  Sign Up
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.